Real World Evidence Undercuts Value Of Hereditary Angioedema Drugs In ICER Analysis Update
Executive Summary
But results of the re-analysis of three HAE treatments aren’t necessarily expected to be typical for RWE-based updates undertaken in the future by the Institute for Clinical and Economic Review.
You may also be interested in...
Medicare Coverage Analysis Of Alzheimer’s Drugs Begins With Focus On Outcomes, Patient Eligibility
Proposed reimbursement decision to be released by 12 January 2022, with a final decision the following April. Biogen's Aduhelm expected to be covered in the interim. Medicare will not consider the cost of treatment in the analysis, but cost may have been a factor in initiating the process.
ICER Will Assess Real World Evidence On Accelerated Approvals After Two Years
Process will incorporate real world evidence into future cost effectiveness updates of already reviewed drugs to supplement the information available prior to launch.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.